Skip to main content
. 2005 Apr 6;7(3):119–130. doi: 10.1186/bcr1023

Table 2.

Clinical efficacy of toremifene versus tamoxifen

Toremifene Tamoxifen


Study [ref.] n ORR TTP (months) n ORR TTP (months)
Hayes et al. [28] 221 21% 5.6 215 19% 5.8
Pyrhonen et al. [29] 214 31% 7.3 201 37% 10.2
Gershanovich et al. [30] 157 21% 4.9 149 21% 5.0
Nomura et al. [27] 62 24% 5.1 60 27% 5.1
Milla-Santos et al. [31] 106 38% 11.9 111 32% 9.2
Meta-analysisa [32] 725 24.0% 4.9 696 25.3% 5.3

Shown is a summary of clinical efficacy data from the randomised phase III trials of toremifene (40–60 mg/day) versus tamoxifen (20–40 mg/day) as first-line endocrine treatment of advanced breast cancer in postmenopausal women (oestrogen receptor status positive or unknown). aThe meta-analysis [32] was published in 1999 and included data from the first four trials [27-30], together with an unpublished small German study, but it did not include the Spanish study [31], which was published in 2001. ORR, objective response rate, including complete response and partial response; TTP, median time to disease progression.